

LIST OF TABLES

Table	Page
2.1 Lipid based nanocarriers apply to several applications	9
2.2 Comparison between properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLCs)	11
2.3 The results of encapsulation bioactive compound and other substances	12
2.4 Summarized the possibility to improve functional meat production by applying lipid based nanocarriers in chicken	15
2.5 Unmodified surface of lipid based nanocarrier influence on particle size in gastrointestinal fluid study.	18
2.6 Modified surface of lipid based nanocarrier improved stability in gastrointestinal fluid study	19
2.7 Lipid based nanocarriers modified surface with PEG improve nanoparticle permeability in intestinal membrane	21
2.8 Targeting modified surface nanoparticle improve intestinal permeability	22
2.9 Nanoparticles surface modification on in vivo pharmacokinetic studies	24
2.10 Targeting of nanoparticles and drug distribution in target organ via oral delivery	26
2.11 The studied of nanoparticles transcytosis and cellular responded by proteomics	30
3.1 Fatty acid composition of crude tuna oil and algal oil	45
3.2 Physical characteristic of n-3 PUFA oils within different type of lipid-nanoparticles	50
3.3 In vitro stability of n-3 PUFA (tuna oil or algal oil, TO or AO) lipid-based targeted (TNP) or not (NP) nanoparticles on particle diameter (nm) during storage at 4°C or room temperature (RT).....	53

LIST OF TABLES (Continued)

Table	Page
3.4 Stability of n-3 PUFA (tuna oil or algal oil, TO or AO) lipid-based targeted (TNP) or not (NP) nanoparticles evaluated with peroxidative value (meq of oxygen/kg fat) during a storage at room temperature (RT) or 4°C	54
3.5 Stability of n-3 PUFA (tuna oil or algal oil, TO or AO) lipid-based targeted (TNP) or not (NP) nanoparticles evaluated with malondialdehyde value (μmol MDA/kg oil) during storage at room temperature (RT) or 4°C	55
3.6 Fatty acid composition of TO oil within different type of lipid-nanoparticles at 2, 4, 8, 12 and 24 h after oral administration.....	57
3.7 Coefficient of transfer efficacy of TO within different type of lipid-nanoparticles at 2, 4, 8, 12 and 24 h after oral administration relative to control.....	58
4.1 Ingredients and nutrient composition of the experimental diets.....	83
4.2 Fatty acid composition of rice bran oil, tuna oil and lipid-based nanoparticles used in the diets	85
4.3 Growth performance of Korat chickens fed diets containing rice bran oil (control), tuna oil (3% TO) or tuna oil in lipid-based nanoparticles (3% TO_TNP)	87
4.4 Carcass composition of Korat chickens fed diets containing rice bran oil (control) of control, tuna oil (3% TO) or tuna oil in lipid-based nanoparticles (3% TO_TNP).....	88
4.5 Meat quality traits of Korat chickens fed diets containing rice bran oil (control) of control, tuna oil (3% TO) or tuna oil in lipid-based nanoparticles (3% TO_TNP).....	89

LIST OF TABLES (Continued)

Table	Page
4.6 Total lipids (g/100 g fresh meat) and fatty acid composition (g/100 g total FA) of breast meat of Korat chickens fed diets containing rice bran oil (control) of control, tuna oil (3% TO) or tuna oil in lipid-based nanoparticles (3% TO_TNP).....	90
4.7 Total lipids (g/100 g fresh meat) and fatty acid composition (g/100 g total FA) of thigh meat of Korat chickens fed diets containing rice bran oil (control), tuna oil (3% TO) or tuna oil in lipid-based nanoparticles (3% TO_TNP)	91
4.8 Hematology parameters of Korat chickens fed diets containing rice bran oil (control) of control, tuna oil (3% TO) or tuna oil in lipid-based nanoparticles (3% TO_TNP).....	93
4.9 Biochemical parameters in plasma of Korat chicken fed diets containing rice bran oil (control) of control, tuna oil (3% TO) or tuna oil in lipid-based nanoparticles (3% TO_TNP).....	94
5.1 Biochemical parameters in plasma of Korat chicken fed diets containing rice bran oil (control) of control, tuna oil (3% TO) or tuna oil in lipid-based nanoparticles (3% TO_TNP).....	129
5.2 The DAPs from pairwise comparisons of NC vs PC and NC vs TNP conditions classified via PPI	136